“new drugs” and require a 3-phase clinical development program. For vaccines developed abroad but tested in India, CDSCO requires bridging Phase 3 studies for immunogenicity and safety. Vaccine trials must be approved by the Drug Controller General of India (DCGI), reviewed by the Subject Expert Committee (SEC), and registered with the Clinical Trials Registry-India (CTRI).

Ethics Committee Oversight

ICMR mandates that all vaccine trials undergo prior review and approval by Institutional Ethics Committees (IECs). Vaccine trials involving vulnerable populations, such as children, elderly, or immunocompromised individuals, require additional scrutiny and informed consent safeguards.

Fast Track Approvals During COVID-19

During the pandemic, the Ministry of Health introduced expedited review procedures for COVID-19 vaccine trials. DCGI allowed rolling data submissions, accelerated ethics approvals, and overlapping study phases to expedite vaccine development while maintaining scientific integrity.

Core Insights from Indian Phase 3 Vaccine Trials

1. Covaxin (BBIL-ICMR)

Bharat Biotech’s Covaxin was India’s first indigenously developed COVID-19 vaccine. The Phase 3 trial enrolled over 25,000 participants across 25+ sites in India. It was a randomized, double-blind, placebo-controlled trial measuring efficacy against symptomatic COVID-19.

• Primary Endpoint: Prevention of symptomatic COVID-19 infection
• Result: Efficacy of ~77.8% (as per peer-reviewed publication in The Lancet)
• Challenges: Cold chain storage, rapid site selection, volunteer follow-up during lockdowns

2. Covishield (Oxford-AstraZeneca, manufactured by Serum Institute of India)

The Indian arm of the global Phase 3 trial enrolled over 1,600 subjects. SII followed CDSCO guidance and ICMR support to conduct bridging immunogenicity studies in parallel with international trials. The study design followed WHO and EMA recommendations on vaccine safety and reactogenicity assessments.

Despite being a bridging trial, India’s Covishield study generated robust data that contributed to emergency use authorization (EUA) approvals across multiple countries, including WHO prequalification.

3. ZyCoV-D (Zydus Cadila’s DNA Vaccine)

This was the world’s first plasmid DNA vaccine against SARS-CoV-2. The Phase 3 trial enrolled over 28,000 participants and included adolescents aged 12–18 years, a first in India. The vaccine was tested across 50+ centers with 2:1 randomization and active safety surveillance.

4. Sputnik V (Dr. Reddy’s Laboratories & Gamaleya Institute)

India hosted bridging Phase 3 trials for the Russian Sputnik V vaccine. CDSCO required India-specific safety and immunogenicity data before EUA. The trial used a heterologous prime-boost regimen (rAd26 + rAd5) and faced challenges with matching cold chain logistics and strain variation monitoring.

5. mRNA Vaccines: Limited Phase 3 Presence

While Pfizer-BioNTech and Moderna’s mRNA vaccines did not conduct Phase 3 trials in India, their Indian deployment prompted regulatory discussions on the need for bridging studies or post-marketing surveillance under special access rules.

Design Features in Indian Phase 3 Vaccine Trials

• Randomized, placebo-controlled, multi-center designs
• High emphasis on adverse event monitoring (AEFI protocols)
• Active and passive surveillance mechanisms
• Biological sample storage and central lab analysis for immunogenicity
• Digital consent and telehealth follow-up during COVID-19 waves

Data Management & Regulatory Review

Sponsors were required to submit periodic safety update reports (PSURs), serious adverse event (SAE) reports to CDSCO, and final clinical study reports (CSRs). Data monitoring committees (DMCs) ensured real-time safety review, often with international observers. Regulatory submissions followed NDCTR guidance and included ICH E3-compatible formats.

Recruitment Challenges & Solutions

During COVID-19, enrollment in vaccine trials was complex due to movement restrictions, vaccine hesitancy, and high dropout risks. Sponsors collaborated with hospitals, NGOs, and community leaders to raise awareness. Centralized call centers and transportation reimbursements helped improve retention.

Best Practices and Preventive Measures

• Develop clear inclusion/exclusion criteria and site SOPs for rapid enrollment
• Engage with local communities to manage vaccine hesitancy and misinformation
• Prequalify central labs for neutralizing antibody assays and T-cell assessments
• Use centralized electronic data capture (EDC) systems for consistency
• Ensure continuous training of site staff on SAE reporting, GCP, and protocol compliance

Scientific and Regulatory Evidence

• CDSCO Guidance on COVID-19 Vaccine Trials
• ICMR Ethical Guidelines (2017) – Vaccine-specific provisions
• WHO Target Product Profiles (TPPs) for COVID-19 vaccines
• ICH E6(R2), ICH E3 – Trial conduct and report writing
• EMA and US FDA guidance on vaccine development and risk-based monitoring

Special Considerations in Indian Settings

Cold Chain and Logistics

Phase 3 vaccine trials often involved two-dose regimens with cold-chain sensitive vials. Ensuring 2–8°C storage at remote sites was a major logistical effort. Remote temperature monitoring and insulated transport boxes were deployed across all sponsor sites.

Adolescents and Pediatrics

With ZyCoV-D and Covaxin extending trials to adolescent populations, ethics approvals included pediatric specialists and additional informed consent/assent procedures. Specialized AE monitoring protocols were followed.

Multilingual Consent Forms

Due to India’s linguistic diversity, consent documents were translated into over 10 languages, with back-translation and comprehension testing. This ensured ethical compliance and reduced legal exposure.

When Sponsors Should Engage Regulators

• Before protocol finalization – for guidance on bridging or standalone trials
• Before enrolling pediatric or vulnerable populations
• When requesting fast-track or EUA pathways
• For post-trial access or public health use commitments
• To resolve SAE reporting discrepancies or protocol deviations

FAQs

1. Is Phase 3 mandatory for vaccines developed abroad?

Yes, unless WHO prequalified. CDSCO often mandates bridging Phase 3 trials to evaluate Indian population safety and immunogenicity before market approval.

2. How large are Indian Phase 3 trials?

They typically enroll 10,000–30,000 participants depending on disease prevalence, trial design, and platform technology.

3. Are Indian Phase 3 results accepted globally?

Yes. Trials conducted per ICH GCP and NDCTR are considered credible by WHO, EMA, and many other regulators if data quality is assured.

4. How long do Phase 3 trials take in India?

Typically 6–12 months including recruitment, follow-up, and final analysis, though pandemic urgency accelerated many timelines to 3–6 months with real-time reviews.

5. What endpoints are commonly used?

Primary endpoints include symptomatic infection rates, severe disease prevention, and neutralizing antibody levels. Secondary endpoints may include hospitalization and death reduction.

6. Can multiple sponsors collaborate on Phase 3 in India?

Yes, consortium-based models are allowed, especially under public-private partnerships or government-supported platforms like ICMR or DBT.

7. What role does CTRI play?

All vaccine trials must be registered with CTRI before enrollment begins, per ICMR and CDSCO mandates, ensuring public access to trial data and compliance.

Conclusion

Phase 3 vaccine trials are a cornerstone of public health preparedness and scientific credibility. India’s robust execution of multiple COVID-19 vaccine trials demonstrated operational excellence, regulatory responsiveness, and scientific integrity. With its well-established infrastructure and evolving policies, India is poised to remain a key hub for global vaccine research and development, far beyond the COVID-19 era.